In this perspective in the present study we analyzed the predictive value of B4GALT1 in a clinical trial of CRC patients [37] treated with anti-EGFR in monotherapy, and we showed that the downregulated expression of this gene is significantly associated with poor response to cetuximab therapy, particularly in the CRC cases bearing WT-KRAS. The gene discussed is B4GALT1; the disease is colorectal carcinoma.